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CV events and T2DM. CONCLUSIONS: Orlistat is a cost-effective treatment to aid
weight reduction in primary care when using a threshold of £20,000 per QALY.
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OBJECTIVES: As part of a medico-economic study on a fibrin sealant used in ortho-
pedic surgery to decrease allogeneic transfusion requirement, this study was con-
ducted to evaluate the overall cost of transfusion from hospital perspective.
METHODS:A multicenter prospective study was carried out from March 14, 2011 to
June 1, 2011 in orthopedic surgery wards of 3 French university hospitals. A micro-
costing has been developed to identify global costs of transfusion through: the
acquisition cost of red blood cell (RBC), supplies used for a transfusion, and times
spent by medical and nurse staff for the management of the transfusion timed by
a pharmacy resident with a stopwatch. Corresponding costs for staff were esti-
mated from mean salaries for medical and non medical staff in 2011.RESULTS: Five
transfusions were observed in each site. A physician spent 1’01” 43” (mean 
standard deviation) for the prescription of RBC. Personal care assistants and hos-
pital workers brought samples to the Blood Bank (BB), transmitted the document to
the BB, and delivered RBC to the ward which took 10’17” 05’46” and 10’47” 03’20”
respectively. Nurses spent 52’23” 04’39” for the control of the documents, the
ultimate pre-transfusion control at patient’s bedside, the administration of RBC
and the monitoring of the transfusion. No adverse event occurred during the study.
The mean global cost of the transfusion of a RBC was estimated at 254 Euros.
Regarding global cost, management of transfusion was estimated at 31 Euros rep-
resenting 12% of the overall cost of transfusion. CONCLUSIONS: The study shows
the heavy workload represented by each transfusion for a nurse in the context of
shortage of nurses. These results may be helpful to fill a pharmacoeconomic model
used to estimate the incremental cost effective of using fibrin sealant in orthopedic
surgery.
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OBJECTIVES: Evaluate the relative impact of migraine-related outcomes using gen-
eralized healthy-time equivalences (HTE). METHODS: A best-practice conjoint
analysis or discrete-choice experiment (DCE) evaluated migraine-related outcomes
reported in the Completeness of Response Survey (CORS). We elicited patients’
trade-off preferences for migraine symptoms with different clinically relevant du-
rations, including symptom-free time. Preference-parameter estimates were used
to determine the amount of symptom-free time that was utility-equivalent to 24-
hour migraine episode profiles described by acute headache, post-headache, and
symptom-free phases. These HTEs quantify the impact of migraine-related out-
comes using a fully general utility-theoretic conceptual framework. Unlike quality-
adjusted life years (QALYs), HTEs do not require assuming that utility of a brief, but
severe, outcome is a simple fraction of a quality-adjusted year. Also unlike QALYs,
HTEs do not require risk neutrality, and easily account for personal characteristics
that may determine preferences for health outcomes. RESULTS: A total of 539
people with a self-reported physician diagnosis of migraine completed the survey.
As expected, migraineurs were negatively affected by the duration of headache-
phase and post-headache-phase symptoms. However, for some groups in the sam-
ple we found no statistical difference in relative preferences for different pain
severities in the acute headache phase. Subjects had clear preferences for different
levels of daily-activity limitations experienced during the post-headache phase.
Results also showed that subjects in the sample were averse to risk. We also found
preference heterogeneity based on individual characteristics. CONCLUSIONS: This
study demonstrates the feasibility of obtaining standardized healthy-time equiv-
alences derived from clinically-relevant symptom-duration tradeoff data as a fea-
sible alternative to QALYs for acute, self-limiting conditions. The results also sug-
gest that the assumptions associated with the use of conventional QALYs are not
met by our sample of migraineurs; adding to the mounting body of evidence that
encourages the use of more flexible utility-theoretic measures of quality-adjusted
time.
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OBJECTIVES: Previous studies have examined the humanistic burden of rheuma-
toid arthritis; however, less research has been conducted to understand the factors
that are most strongly associated with the health-related quality of life of these
patients. METHODS: Data from the European 2010 National Health and Wellness
Survey (an annual survey of respondents from France, Germany, Italy, Spain, and
the UK) were used in the current study. Only respondents who reported being
diagnosed with RA (N498) were included in the analyses. Health state utilities
(SF-6D), derived from the SF-12, were examined on a bivariate level across a variety
of subgroups (e.g., years diagnosed, treatment status, comorbidities, joints af-
fected, etc). Health state utilities were also predicted from demographic and pa-
tient characteristic information using multiple regressions. RESULTS:A total of 498
patients (0.86%) reported being diagnosed with RA. These patients were mostly
female (64.3%) and had an average age of 52.3 years. Most patients were diagnosed
with RA for more than 10 years (55.8%). Several demographic and patient charac-
teristic factors were significantly associated with health state utilities. RA patients
in Spain (Adjusted Mean0.60) and Italy (Adjusted mean0.53) had the highest and
lowest, respectively, utility scores. Severe RA (Adjusted mean0.51), comorbid
Crohn’s disease (Adjusted mean0.52), and RA affecting the spine (Adjusted
mean0.54) were associated with the largest decrements in utility scores (all
ps.05). CONCLUSIONS: Although previous studies have documented the burden
of RA in Europe, the current study suggests that burden is not uniform. Certain
geographies, particularly Italy, are associated with a greater burden for patients
with RA. Similarly, patient characteristics, such as arthritis of the spine and comor-
bid Crohn’s disease, have a large effect on the quality of life of these patients. These
results suggest a more comprehensive assessment of patient characteristics is
necessary to fully capture the quality of life burden of RA.
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OBJECTIVES: To analyze QoL of patients with chronic pain due to osteoarthritis of
the knee (OA) or low back pain (LBP) using the EQ-5D questionnaire in phase III
trials with tapentadol prolonged release (PR) and oxycodone controlled release
(CR).METHODS: Three phase III trials in OA and LBP with the same design included
the EQ-5D questionnaire to measure utilities of patients with chronic pain treated
with either tapentadol PR, oxycodone CR or placebo. Utilities were obtained at
baseline and endpoint (15 weeks). An analysis was performed to explore how
EQ-5D distinguished among various health states. RESULTS: Mean utility of all
patients treated with tapentadol PR (N978) increased from 0.42 at baseline to 0.60
at endpoint, and for patients treated with oxycodone CR (N998) from 0.43 at
baseline to 0.56 at endpoint, and for patients treated with placebo (N990) from
0.41 at baseline to 0.55 at endpoint. The increase in utility was significantly higher
(p0.001) in patients treated with tapentadol compared to those treated with oxy-
codone or placebo. Presence and severity of adverse events, as well as insufficient
pain relief substantially decreased utility values in both tapentadol and oxycodone
treatment groups. Whereas the highest utilities were seen in the groups of patients
who had30% pain improvement and patients who tolerated the treatment (0.69-
0.72), patients who withdrew due to an adverse event or due to lack of efficacy had
much lower utilities (0.40-0.51). CONCLUSIONS: EQ-5D utilities of OA and LBP pa-
tients increased significantly compared to baseline when treated with tapentadol
PR or oxycodone CR, whereby the increase was significantly higher with tapentadol
PR. Sufficient pain relief and reduction of severe treatment-related adverse events
resulted in a large beneficial impact on EQ-5D utility values. This analysis clearly
demonstrates that the EQ-5D is a useful tool to measure QoL in pain studies.
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OBJECTIVES: Compare health measurements of females with bleeding disorders
(FBD) to males with von Willebrand disease (VWD) and females in the general
population (FGP). METHODS: Subjects 12yrs of age, with VWD and FBD in the
Canadian national registry were eligible for assessment. Health status and health-
related quality of life (HRQL) were measured using the Health Utilities Index Mark
3 (HUI3). The results were compared with normative data by age and gender from
the 2002/3 Joint Canada / United States Survey of Health and from the 1991 Cana-
dian General Social Survey. Mean differences and proportions were assessed using
t-test and chi square, respectively. Differences 0.05 in mean HRQL scores and
10% for proportions were considered important. Statistical significance was set at
p0.05. RESULTS: 411 HUI3 assessments were analyzed. Among 20-79 year old
FBD, mean HRQL scores were lower (diff0.150; p0.05) than in FGP. For those45
years, FBD had lower HRQL scores (diff0.080; p0.027) than males with VWD. No
difference between males with VWD and FBD 45 years of age was observed
(p0.871). Excellent health was self-reported by 18.4% of females from the registry
compared to 22.7% (p0.05) of FGP and 29.9% (p0.02) of males with VWD. Between
FDB and FGP important differences (p0.001) in the proportion reporting disability
were observed for HUI3 attributes vision, emotion, cognition, and pain for those
45 years, and ambulation, dexterity, emotion and pain for those 45 years. Be-
tween FBD and males with VWD an important difference (p0.005) in the propor-
tion reporting disability was observed for pain. FBD have similar HRQL (0.72) to
moderate (0.73) and severe (0.71) HIV-negative haemophiliacs. CONCLUSIONS: Fe-
males with bleeding disorders have greater morbidity than females in the general
population or males with VWD.
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CHRONIC PAIN: PATIENT TREATMENT PREFERENCES - A DISCRETE CHOICE
EXPERIMENT
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